Takeda Pharmaceutical (NYSE:TAK - Get Free Report) was upgraded by equities research analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating in a note issued to investors on Wednesday, Marketbeat.com reports.
Takeda Pharmaceutical Stock Performance
NYSE:TAK traded down $0.57 during midday trading on Wednesday, reaching $14.15. 2,387,644 shares of the company traded hands, compared to its average volume of 1,820,051. The firm has a market capitalization of $45.02 billion, a price-to-earnings ratio of 35.34, a price-to-earnings-growth ratio of 0.24 and a beta of 0.39. The company has a fifty day moving average price of $14.35 and a 200 day moving average price of $13.92. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72. Takeda Pharmaceutical has a twelve month low of $12.58 and a twelve month high of $15.37.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. On average, analysts expect that Takeda Pharmaceutical will post 1.64 EPS for the current fiscal year.
Institutional Trading of Takeda Pharmaceutical
Large investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. increased its holdings in shares of Takeda Pharmaceutical by 17.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 187,165 shares of the company's stock valued at $2,661,000 after purchasing an additional 27,628 shares during the period. FMR LLC increased its stake in Takeda Pharmaceutical by 10.9% during the 3rd quarter. FMR LLC now owns 2,908,918 shares of the company's stock valued at $41,365,000 after buying an additional 286,052 shares during the period. BNP Paribas Financial Markets increased its stake in Takeda Pharmaceutical by 416.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company's stock valued at $46,000 after buying an additional 2,596 shares during the period. Verition Fund Management LLC bought a new stake in shares of Takeda Pharmaceutical during the 3rd quarter worth about $1,533,000. Finally, Erste Asset Management GmbH acquired a new stake in shares of Takeda Pharmaceutical in the 3rd quarter worth approximately $52,000. 9.17% of the stock is currently owned by institutional investors and hedge funds.
About Takeda Pharmaceutical
(
Get Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Read More
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
